A 02 - HangZhou Converd
Alternative Names: A02 - Hangzhou ConverdLatest Information Update: 28 Apr 2023
At a glance
- Originator Hangzhou Converd
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Gene transference; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in China
- 29 Mar 2019 Preclinical trials in Cancer in China before March 2019
- 29 Mar 2019 Pharmacodynamics data from a preclinical studies in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)